Gilead price target raised to $145 from $140 at Truist

1 week ago 12

TipRanks

Wed, January 28, 2026 astatine 7:20 AM CST 1 min read

Truist raised the firm’s price target connected Gilead (GILD) to $145 from $140 and keeps a Buy standing connected the shares arsenic portion of a broader probe enactment previewing Q4 net successful Biotech. The steadfast is adjusting Yeztugo numbers heading into Q4 EPS, tweaking its timelines based connected updated guidance for near-term launches, including BIC/LEN successful 2H25, US motorboat of Hepcludex, and enlargement accidental for Livdelzi, and besides fine-tuning its estimates for the anito-cel motorboat pursuing FDA guidance, the expert tells investors successful a probe note.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected GILD:

Disclaimer & DisclosureReport an Issue

Gilead terms people raised to $156 from $140 astatine Citi
Looking for Exposure to UnitedHealth Stock (UNH) up of Q4 Earnings? Here’s How to Buy Without the Risk
Gilead terms people raised to $155 from $145 astatine UBS
Why Gilead Sciences Is Suddenly Back successful the Spotlight
Gilead announces NEJM Phase 3 survey information for Trodelvy+Keytruda

Read Entire Article